

RealRate

PHARMACEUTICAL 2020











RealRate

PHARMACEUTICAL 2020

Altimmune Inc. Rank 75 of 358

The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Altimmune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 148% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	39,395
Cost of Goods Sold	0
Intangible Assets	12,732
Liabilities, Current	3,923
Liabilities, Non-Current	0
Other Assets	827
Other Compr. Net Income	20
Other Expenses	942
Other Liabilities	4,615
Other Net Income	886
Other Revenues	5,801
Property and Equipment	1,104
Research and Development	17,766
Selling, General and Administrative Expense	8,501

Output Variable	Value in 1000 USD
Assets	54,058
Liabilities	8,538
Expenses	27,208
Revenues	5,801
Stockholders Equity	45,520
Net Income	-20,520
Comprehensive Net Income	-20,510
Economic Capital Ratio	185%

